Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 4/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | PNLIP | P16233 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13715139 | 0.89 | KEAP1 (0.61) | HSPB1SCN4AKEAP1GCKAR | |
| SCHEMBL4857147 | 0.80 | HSPB1 (0.58) | HSPB1SCN4ABRD4ALDH1A1 | |
| SCHEMBL25328315 | 0.79 | NR4A1 (0.52) | PARP10BRAFHDAC1ALDH1A1HDAC3 | |
| SCHEMBL31151866 | 0.79 | NR4A1 (0.52) | PARP10BRAFHDAC1ALDH1A1HDAC3 | |
| SCHEMBL20154948 | 0.78 | EPAS1 (0.46) | HSPB1SCN4AKEAP1BRD4ALDH1A1 | |
| SCHEMBL183930 | 0.78 | KEAP1 (0.70) | KEAP1HDAC1ALDH1A1HDAC6 | |
| SCHEMBL31230207 | 0.78 | KEAP1 (0.70) | KEAP1HDAC1ALDH1A1HDAC6 | |
| Hydrochloric Acid SCHEMBL4362930 | 0.76 | KEAP1 (0.68) | KEAP1HDAC1ALDH1A1HDAC6 | |
| SCHEMBL9656997 | 0.75 | BRD4 (0.47) | HSPB1SCN4APARP10BRD4AR | |
| SCHEMBL13743676 | 0.75 | HSPB1 (0.51) | HSPB1SCN4AARMETMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456185-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456185-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456185-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | DUNN JAMES P | 2007-07-19 | — | — | US | disclosed |
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | DUNN JAMES P | 2007-07-19 | — | — | US | disclosed |
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | DUNN JAMES P | 2007-07-19 | — | — | US | disclosed |
| US-7238698-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238698-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238698-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1620408-A2 | QUINAZOLINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004092144-A2 | QUINAZOLINE COMPOUNDS USEFUL AS P38 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209904-A1 | Substituted quinazoline compounds useful as P38 kinase inhibitors | ROCHE PALO ALTO LLC | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | MAPK1, MAPK7, MAPK3 | HSPB1 953/4885SCN4A 1570/4885PARP10 3376/4885 |
| US-20040209904-A1 | Substituted quinazoline compounds useful as P38 kinase inhibitors | MAPK1, MAPK4, MAPK7 | HSPB1 638/4885SCN4A 1049/4885PARP10 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.